Zoetis Inc. (NYSE:ZTS) Shares Sold by Cynosure Group LLC

Cynosure Group LLC lessened its position in Zoetis Inc. (NYSE:ZTS) by 7.3% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 2,500 shares of the company’s stock after selling 198 shares during the period. Cynosure Group LLC’s holdings in Zoetis were worth $488,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in ZTS. Thematics Asset Management boosted its stake in shares of Zoetis by 4.6% in the third quarter. Thematics Asset Management now owns 35,354 shares of the company’s stock valued at $6,907,000 after buying an additional 1,557 shares in the last quarter. J. Stern & Co. LLP lifted its stake in shares of Zoetis by 5.7% in the third quarter. J. Stern & Co. LLP now owns 199,953 shares of the company’s stock valued at $39,067,000 after purchasing an additional 10,806 shares during the period. Lazard Freres Gestion S.A.S. grew its position in Zoetis by 28.5% during the third quarter. Lazard Freres Gestion S.A.S. now owns 890,953 shares of the company’s stock worth $174,074,000 after buying an additional 197,337 shares during the period. Avestar Capital LLC increased its holdings in Zoetis by 15.1% in the third quarter. Avestar Capital LLC now owns 2,945 shares of the company’s stock valued at $575,000 after buying an additional 386 shares in the last quarter. Finally, Brooklyn Investment Group boosted its stake in shares of Zoetis by 9.3% during the 3rd quarter. Brooklyn Investment Group now owns 3,584 shares of the company’s stock worth $700,000 after acquiring an additional 304 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 0.6 %

Shares of ZTS opened at $176.74 on Thursday. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The firm has a market cap of $79.74 billion, a PE ratio of 33.22, a price-to-earnings-growth ratio of 2.70 and a beta of 0.90. The company’s fifty day moving average is $184.51 and its two-hundred day moving average is $180.81. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92.

Zoetis (NYSE:ZTS) last posted its earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. The firm had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The company’s revenue was up 11.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.36 EPS. Analysts forecast that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be given a dividend of $0.432 per share. The ex-dividend date is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a yield of 0.98%. Zoetis’s dividend payout ratio (DPR) is 32.52%.

Analyst Ratings Changes

A number of research firms have commented on ZTS. JPMorgan Chase & Co. boosted their target price on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Piper Sandler raised their price objective on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Stifel Nicolaus raised their price target on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, September 18th. Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Finally, BTIG Research upped their target price on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Zoetis has a consensus rating of “Buy” and an average target price of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.